MedTrace Logo

Efficacy and Safety of SCT200 in Patients With Advanced Squamous Non-small Cell Lung Cancer

NCT03808701 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2019-01-17

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of recombinant anti-EGFR monoclonal antibody（SCT200）in patients with advanced squamous non-small cell lung cancer treated after failure of Two chemotherapy regimens (including Platinum-based drugs).

Conditions

  • Advanced Squamous Non-small Cell Lung Cancer

Interventions

DRUG

SCT200

Recombinant Anti-EGFR Monoclonal Antibody

Sponsors & Collaborators

  • Sinocelltech Ltd.

    lead INDUSTRY

Principal Investigators

  • CHENG YING, MD · Jilin Provincial Cancer Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-31
Primary Completion
2019-12-31
Completion
2019-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03808701 on ClinicalTrials.gov